Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples